Free Trial
→ If You Keep Cash In A U.S. Bank Account… Read This NOW (From Banyan Hill Publishing) (Ad)tc pixel Free BVS Stock Alerts

Bioventus (BVS) Financials

Bioventus logo
$6.94 -0.02 (-0.29%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$6.76 -0.18 (-2.52%)
As of 10/24/2025 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Bioventus

Annual Income Statements for Bioventus

This table shows Bioventus' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -159 -156 -34
Consolidated Net Income / (Loss)		 -213 -196 -44
Net Income / (Loss) Continuing Operations		 -145 -121 -44
Total Pre-Tax Income 		-189 -121 -49
Total Operating Income		 -167 -82 -12
Total Gross Profit		 331 328 388
Total Revenue		 512 512 573
Operating Revenue		 512 512 573
Total Cost of Revenue		 181 184 185
Operating Cost of Revenue		 181 184 185
Total Operating Expenses		 498 410 400
Selling, General & Admin Expense		 332 304 341
Research & Development Expense		 24 13 14
Depreciation Expense		 9.75 8.84 7.65
Other Operating Expenses / (Income)		 0.00 3.58 0.29
Impairment Charge		 125 79 36
Restructuring Charge		 6.78 0.84 -0.05
Other Special Charges / (Income)		 1.10 0.72 1.42
Total Other Income / (Expense), net		 -22 -39 -37
Interest & Investment Income		 -12 -41 -39
Other Income / (Expense), net		 -9.77 1.29 1.65
Income Tax Expense		 -44 0.09 -5.29
Net Income / (Loss) Discontinued Operations		 -69 -74 0.00
Net Income / (Loss) Attributable to Noncontrolling Interest		 -55 -39 -10
Basic Earnings per Share		 ($2.59) ($2.49) ($0.52)
Weighted Average Basic Shares Outstanding		 61.39M 62.65M 64.55M
Diluted Earnings per Share		 ($2.59) ($2.49) ($0.52)
Weighted Average Diluted Shares Outstanding		 61.39M 62.65M 64.55M
Weighted Average Basic & Diluted Shares Outstanding		 78.05M 79.17M 81.94M

Quarterly Income Statements for Bioventus

This table shows Bioventus' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 10/1/2022 12/31/2022 4/1/2023 7/1/2023 9/30/2023 12/31/2023 3/30/2024 6/29/2024 9/28/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -108 -32 -139 -3.68 -7.30 -6.10 -4.57 -24 -4.82 -0.16
Consolidated Net Income / (Loss)		 -146 -45 -174 -4.73 -8.79 -7.66 -5.98 -32 -5.42 -0.32
Net Income / (Loss) Continuing Operations		 -101 -21 -100 -4.73 -8.79 -7.66 -5.98 -32 -5.42 -0.32
Total Pre-Tax Income 		-131 -32 -100 -4.35 -8.19 -8.41 -5.08 -39 -4.83 0.23
Total Operating Income		 -127 -16 -92 6.75 2.42 1.17 5.33 -29 4.07 7.99
Total Gross Profit		 85 74 74 89 79 86 88 104 94 103
Total Revenue		 129 126 119 137 121 135 129 151 139 154
Operating Revenue		 129 126 119 137 121 135 129 151 139 154
Total Cost of Revenue		 44 52 45 48 42 49 41 48 45 51
Operating Cost of Revenue		 44 52 45 48 42 49 41 48 45 51
Total Operating Expenses		 211 90 166 82 76 85 83 133 89 95
Selling, General & Admin Expense		 79 77 81 75 70 78 78 95 81 87
Research & Development Expense		 4.61 5.95 3.77 3.40 3.02 3.26 2.60 3.99 3.81 3.25
Depreciation Expense		 2.26 1.54 2.13 2.29 2.32 2.10 1.76 2.06 2.07 1.77
Impairment Charge		 125 - 79 0.00 0.00 - 0.00 32 2.03 2.46
Restructuring Charge		 0.58 4.62 0.32 0.62 -0.03 -0.07 0.00 0.00 0.00 -0.05
Other Special Charges / (Income)		 0.28 0.28 0.29 0.24 -0.10 0.29 0.30 0.30 0.48 0.35
Total Other Income / (Expense), net		 -3.72 -17 -8.11 -11 -11 -9.57 -10 -10 -8.91 -7.76
Interest & Investment Income		 -3.60 -7.39 -9.69 -11 -10 -10 -10 -9.92 -9.53 -9.00
Other Income / (Expense), net		 -0.12 -9.41 1.59 -0.51 -0.49 0.71 -0.06 -0.16 0.63 1.24
Income Tax Expense		 -30 -11 -0.15 0.38 0.60 -0.75 0.91 -7.34 0.59 0.55
Net Income / (Loss) Attributable to Noncontrolling Interest		 -37 -13 -35 -1.05 -1.49 -1.56 -1.41 -8.12 -0.60 -0.16
Basic Earnings per Share		 ($1.76) ($0.53) ($2.24) ($0.06) ($0.12) ($0.07) ($0.07) ($0.37) ($0.07) ($0.01)
Weighted Average Basic Shares Outstanding		 61.67M 61.39M 62.12M 62.55M 62.82M 62.65M 63.38M 64.06M 65.26M 64.55M
Diluted Earnings per Share		 ($1.76) ($0.53) ($2.24) ($0.06) ($0.12) ($0.07) ($0.07) ($0.37) ($0.07) ($0.01)
Weighted Average Diluted Shares Outstanding		 61.67M 61.39M 62.12M 62.55M 62.82M 62.65M 63.38M 64.06M 65.26M 64.55M
Weighted Average Basic & Diluted Shares Outstanding		 77.74M 78.05M 78.27M 78.58M 78.75M 79.17M 79.61M 80.97M 81.15M 81.94M

Annual Cash Flow Statements for Bioventus

This table details how cash moves in and out of Bioventus' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 -67 5.13 4.62
Net Cash From Operating Activities		 -14 15 39
Net Cash From Continuing Operating Activities		 -11 18 39
Net Income / (Loss) Continuing Operations		 -145 -121 -44
Consolidated Net Income / (Loss)		 -213 -196 -44
Net Income / (Loss) Discontinued Operations		 -69 -74 0.00
Depreciation Expense		 55 57 50
Non-Cash Adjustments To Reconcile Net Income		 153 84 46
Changes in Operating Assets and Liabilities, net		 -75 -3.13 -13
Net Cash From Discontinued Operating Activities		 -2.13 -2.17 0.00
Net Cash From Investing Activities		 -116 16 23
Net Cash From Continuing Investing Activities		 -12 27 23
Purchase of Property, Plant & Equipment		 -1.48 -7.36 -1.01
Acquisitions		 -10 0.00 -0.71
Divestitures		 0.00 35 25
Other Investing Activities, net		 -0.08 0.00 0.00
Net Cash From Discontinued Investing Activities		 -105 -12 0.00
Net Cash From Financing Activities		 62 -27 -55
Net Cash From Continuing Financing Activities		 62 -27 -55
Repayment of Debt		 -45 -91 -62
Issuance of Debt		 105 64 0.00
Issuance of Common Equity		 5.82 0.78 2.44
Other Financing Activities, net		 -3.35 0.00 4.50
Effect of Exchange Rate Changes		 0.52 0.63 -2.56

Quarterly Cash Flow Statements for Bioventus

This table details how cash moves in and out of Bioventus' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 10/1/2022 12/31/2022 4/1/2023 7/1/2023 9/30/2023 12/31/2023 3/30/2024 6/29/2024 9/28/2024 12/31/2024
Net Change in Cash & Equivalents		 -6.62 -2.55 15 -18 -2.56 10 -12 6.82 11 -1.49
Net Cash From Operating Activities		 -0.70 5.24 2.49 11 -8.32 10 -6.01 15 10 19
Net Cash From Continuing Operating Activities		 0.16 6.52 4.66 11 -8.32 10 -6.01 15 10 19
Net Income / (Loss) Continuing Operations		 -101 -21 -100 -4.73 -8.79 -7.66 -5.98 -32 -5.42 -0.32
Consolidated Net Income / (Loss)		 -146 -45 -174 -4.73 -8.79 -7.66 -5.98 -32 -5.42 -0.32
Depreciation Expense		 14 17 16 15 14 12 12 13 12 12
Non-Cash Adjustments To Reconcile Net Income		 129 15 82 -2.34 2.70 1.83 1.99 36 3.35 4.53
Changes in Operating Assets and Liabilities, net		 -42 -3.46 5.92 3.27 -16 3.73 -14 -1.96 0.11 2.70
Net Cash From Investing Activities		 -56 -3.40 -15 34 -2.04 -0.59 -1.00 -0.08 -0.06 24
Net Cash From Continuing Investing Activities		 49 -3.40 -3.56 34 -2.04 -0.59 -1.00 -0.08 -0.06 24
Purchase of Property, Plant & Equipment		 -1.65 5.16 -3.56 -1.40 -2.04 -0.37 -0.29 -0.08 -0.06 -0.57
Divestitures		 - - - - - -0.22 - - - 25
Net Cash From Financing Activities		 51 -5.44 27 -62 8.23 -0.01 -4.24 -7.85 0.36 -43
Net Cash From Continuing Financing Activities		 51 -5.44 27 -62 8.23 -0.01 -4.24 -7.85 0.36 -43
Repayment of Debt		 -29 -6.52 -20 -60 -7.17 -3.83 -3.24 -8.45 -0.19 -50
Issuance of Common Equity		 0.48 1.08 0.08 0.14 0.40 0.16 0.18 0.61 0.55 1.10
Other Financing Activities, net		 - - -1.67 -1.99 - 3.66 -1.18 - - 5.68
Effect of Exchange Rate Changes		 -0.24 1.05 0.46 0.24 -0.44 0.37 -0.54 -0.42 0.47 -2.06

Annual Balance Sheets for Bioventus

This table presents Bioventus' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Total Assets		 1,373 811 728
Total Current Assets		 273 268 276
Cash & Equivalents		 30 37 42
Accounts Receivable		 136 123 127
Inventories, net		 85 91 92
Prepaid Expenses		 19 17 14
Plant, Property, & Equipment, net		 27 37 27
Total Noncurrent Assets		 1,073 506 421
Long-Term Investments		 2.62 3.14 1.89
Goodwill		 7.46 7.46 7.46
Intangible Assets		 640 482 405
Other Noncurrent Operating Assets		 17 13 6.51
Total Liabilities & Shareholders' Equity		 1,373 811 728
Total Liabilities		 960 590 542
Total Current Liabilities		 304 175 210
Short-Term Debt		 33 28 47
Accounts Payable		 37 23 24
Accrued Expenses		 112 120 136
Other Current Liabilities		 3.61 4.82 3.92
Total Noncurrent Liabilities		 656 414 332
Long-Term Debt		 385 367 308
Noncurrent Deferred & Payable Income Tax Liabilities		 2.25 1.21 0.56
Other Noncurrent Operating Liabilities		 40 46 23
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 412 221 186
Total Preferred & Common Equity		 325 174 148
Total Common Equity		 325 174 148
Common Stock		 491 494 506
Retained Earnings		 -165 -322 -355
Accumulated Other Comprehensive Income / (Loss)		 -0.11 0.79 -2.57
Noncontrolling Interest		 87 48 38

Quarterly Balance Sheets for Bioventus

This table presents Bioventus' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 10/1/2022 4/1/2023 7/1/2023 9/30/2023 3/30/2024 6/29/2024 9/28/2024
Total Assets		 1,398 887 837 811 794 792 769
Total Current Assets		 271 309 261 249 266 309 299
Cash & Equivalents		 34 47 29 27 25 32 43
Accounts Receivable		 132 119 120 113 126 137 122
Inventories, net		 77 88 96 98 97 88 90
Prepaid Expenses		 28 17 15 12 18 24 17
Other Current Assets		 - 38 - - - 28 27
Plant, Property, & Equipment, net		 0.00 37 42 40 35 32 29
Total Noncurrent Assets		 1,127 542 534 522 494 451 441
Long-Term Investments		 13 2.62 6.54 6.86 3.21 2.09 1.93
Goodwill		 15 7.46 7.46 7.46 7.46 7.46 7.46
Intangible Assets		 1,056 516 505 493 471 425 415
Noncurrent Deferred & Refundable Income Taxes		 0.00 - - - - 6.88 7.40
Other Noncurrent Operating Assets		 43 16 15 14 12 10 9.78
Total Liabilities & Shareholders' Equity		 1,398 887 837 811 794 792 769
Total Liabilities		 1,019 647 604 585 577 603 583
Total Current Liabilities		 288 196 179 161 173 231 211
Short-Term Debt		 31 41 11 20 36 57 58
Accounts Payable		 19 33 41 18 19 24 17
Accrued Expenses		 117 116 122 119 114 140 129
Other Current Liabilities		 121 6.15 4.67 4.73 4.81 9.74 8.15
Total Noncurrent Liabilities		 731 451 425 424 403 372 371
Long-Term Debt		 393 404 375 375 355 345 345
Noncurrent Deferred & Payable Income Tax Liabilities		 159 0.35 0.00 0.00 1.29 0.00 0.00
Other Noncurrent Operating Liabilities		 178 46 50 49 47 27 26
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 379 240 233 226 217 189 187
Total Preferred & Common Equity		 343 189 183 178 171 151 149
Total Common Equity		 343 189 183 178 171 151 149
Common Stock		 478 493 491 493 497 501 503
Retained Earnings		 -133 -304 -308 -315 -326 -350 -355
Accumulated Other Comprehensive Income / (Loss)		 -1.34 0.41 0.66 0.40 0.33 -0.02 0.45
Noncontrolling Interest		 36 52 50 49 46 38 38

Annual Metrics And Ratios for Bioventus

This table displays calculated financial ratios and metrics derived from Bioventus' official financial filings.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - -
Revenue Growth		 18.85% 0.04% 11.89%
EBITDA Growth		 -367.41% 81.03% 270.01%
EBIT Growth		 -1,769.85% 54.56% 87.15%
NOPAT Growth		 -904.00% 51.13% 85.34%
Net Income Growth		 -2,326.07% 8.33% 77.59%
EPS Growth		 -1,626.67% 3.86% 79.12%
Operating Cash Flow Growth		 -158.88% 213.35% 152.84%
Free Cash Flow Firm Growth		 92.87% 353.99% -27.74%
Invested Capital Growth		 -9.38% -21.83% -14.46%
Revenue Q/Q Growth		 -0.89% 1.91% 3.28%
EBITDA Q/Q Growth		 -17.38% 49.32% 22.85%
EBIT Q/Q Growth		 -15.13% 25.08% 41.58%
NOPAT Q/Q Growth		 -8.07% 17.05% 36.29%
Net Income Q/Q Growth		 -25.22% 15.98% 14.34%
EPS Q/Q Growth		 -25.73% 15.59% 10.34%
Operating Cash Flow Q/Q Growth		 -139.00% 50.23% 29.98%
Free Cash Flow Firm Q/Q Growth		 92.63% 3.87% 153.18%
Invested Capital Q/Q Growth		 -2.57% -1.96% -9.56%
Profitability Metrics		 - - -
Gross Margin		 64.65% 64.06% 67.72%
EBITDA Margin		 -23.75% -4.50% 6.84%
Operating Margin		 -32.66% -15.95% -2.09%
EBIT Margin		 -34.56% -15.70% -1.80%
Profit (Net Income) Margin		 -41.67% -38.18% -7.65%
Tax Burden Percent		 112.89% 161.53% 89.23%
Interest Burden Percent		 106.79% 150.57% 475.38%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -15.11% -8.72% -1.57%
ROIC Less NNEP Spread (ROIC-NNEP)		 -47.02% -49.47% -12.28%
Return on Net Nonoperating Assets (RNNOA)		 -30.01% -53.06% -19.98%
Return on Equity (ROE)		 -45.11% -61.78% -21.55%
Cash Return on Invested Capital (CROIC)		 -5.27% 15.79% 14.02%
Operating Return on Assets (OROA)		 -13.62% -7.37% -1.34%
Return on Assets (ROA)		 -16.42% -17.92% -5.70%
Return on Common Equity (ROCE)		 -37.40% -48.66% -17.04%
Return on Equity Simple (ROE_SIMPLE)		 -65.61% -112.69% -29.63%
Net Operating Profit after Tax (NOPAT)		 -117 -57 -8.39
NOPAT Margin		 -22.86% -11.17% -1.46%
Net Nonoperating Expense Percent (NNEP)		 31.91% 40.76% 10.71%
Return On Investment Capital (ROIC_SIMPLE)		 -14.10% -9.29% -1.55%
Cost of Revenue to Revenue		 35.35% 35.94% 32.28%
SG&A Expenses to Revenue		 64.86% 59.31% 59.46%
R&D to Revenue		 4.66% 2.62% 2.38%
Operating Expenses to Revenue		 97.30% 80.01% 69.81%
Earnings before Interest and Taxes (EBIT)		 -177 -80 -10
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -122 -23 39
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 0.62 2.39 5.76
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.40 0.81 1.49
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.92 1.42 2.44
Enterprise Value to Revenue (EV/Rev)		 1.32 1.60 2.10
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 30.63
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 53.26 30.97
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 7.89 16.04
Leverage & Solvency		 - - -
Debt to Equity		 1.01 1.79 1.91
Long-Term Debt to Equity		 0.93 1.66 1.66
Financial Leverage		 0.64 1.07 1.63
Leverage Ratio		 2.75 3.45 3.78
Compound Leverage Factor		 2.93 5.19 17.99
Debt to Total Capital		 50.35% 64.10% 65.68%
Short-Term Debt to Total Capital		 3.98% 4.52% 8.67%
Long-Term Debt to Total Capital		 46.37% 59.58% 57.01%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 10.48% 7.72% 6.96%
Common Equity to Total Capital		 39.17% 28.18% 27.36%
Debt to EBITDA		 -3.44 -17.12 9.06
Net Debt to EBITDA		 -3.17 -15.38 7.95
Long-Term Debt to EBITDA		 -3.17 -15.91 7.86
Debt to NOPAT		 -3.57 -6.90 -42.36
Net Debt to NOPAT		 -3.29 -6.20 -37.18
Long-Term Debt to NOPAT		 -3.29 -6.42 -36.77
Altman Z-Score		 -0.12 0.31 1.11
Noncontrolling Interest Sharing Ratio		 17.11% 21.24% 20.95%
Liquidity Ratios		 - - -
Current Ratio		 0.90 1.53 1.31
Quick Ratio		 0.55 0.91 0.80
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 -41 104 75
Operating Cash Flow to CapEx		 -915.90% 208.42% 3,856.36%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00
Efficiency Ratios		 - - -
Asset Turnover		 0.39 0.47 0.75
Accounts Receivable Turnover		 3.92 3.96 4.58
Inventory Turnover		 2.47 2.09 2.01
Fixed Asset Turnover		 20.31 16.00 18.02
Accounts Payable Turnover		 6.75 6.17 7.92
Days Sales Outstanding (DSO)		 93.10 92.29 79.64
Days Inventory Outstanding (DIO)		 147.64 174.52 181.27
Days Payable Outstanding (DPO)		 54.05 59.20 46.08
Cash Conversion Cycle (CCC)		 186.70 207.61 214.83
Capital & Investment Metrics		 - - -
Invested Capital		 737 576 493
Invested Capital Turnover		 0.66 0.78 1.07
Increase / (Decrease) in Invested Capital		 -76 -161 -83
Enterprise Value (EV)		 675 817 1,202
Market Capitalization		 203 415 852
Book Value per Share		 $4.18 $2.20 $1.82
Tangible Book Value per Share		 ($4.14) ($4.02) ($3.26)
Total Capital		 830 616 541
Total Debt		 418 395 355
Total Long-Term Debt		 385 367 308
Net Debt		 385 355 312
Capital Expenditures (CapEx)		 1.48 7.36 1.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -29 83 71
Debt-free Net Working Capital (DFNWC)		 1.61 120 112
Net Working Capital (NWC)		 -31 93 65
Net Nonoperating Expense (NNE)		 96 138 35
Net Nonoperating Obligations (NNO)		 324 355 307
Total Depreciation and Amortization (D&A)		 55 57 50
Debt-free, Cash-free Net Working Capital to Revenue		 -5.58% 16.28% 12.31%
Debt-free Net Working Capital to Revenue		 0.32% 23.49% 19.56%
Net Working Capital to Revenue		 -6.14% 18.05% 11.38%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 ($2.59) ($2.49) ($0.52)
Adjusted Weighted Average Basic Shares Outstanding		 61.39M 62.65M 64.55M
Adjusted Diluted Earnings per Share		 ($2.59) ($2.49) ($0.52)
Adjusted Weighted Average Diluted Shares Outstanding		 61.39M 62.65M 64.55M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 78.05M 79.17M 81.94M
Normalized Net Operating Profit after Tax (NOPAT)		 -24 -1.09 18
Normalized NOPAT Margin		 -4.74% -0.21% 3.14%
Pre Tax Income Margin		 -36.91% -23.64% -8.57%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Bioventus

This table displays calculated financial ratios and metrics derived from Bioventus' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 10/1/2022 12/31/2022 4/1/2023 7/1/2023 9/30/2023 12/31/2023 3/30/2024 6/29/2024 9/28/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 18.16% -3.51% 1.51% -2.32% -6.12% 7.62% 8.73% 10.32% 15.04% 13.45%
EBITDA Growth		 -1,787.42% -181.91% -759.63% 145.95% 113.89% 276.83% 123.04% -178.88% 7.77% 50.88%
EBIT Growth		 -6,937.36% -1,299.50% -329.03% 259.43% 101.52% 107.48% 105.82% -573.42% 144.28% 392.48%
NOPAT Growth		 -12,014.52% -396.41% -329.17% 304.05% 101.91% 107.45% 105.79% -535.08% 68.49% -1,442.62%
Net Income Growth		 -6,321.24% -2,270.47% -1,078.22% 40.97% 93.97% 82.94% 96.57% -578.76% 38.33% 95.85%
EPS Growth		 -5,766.67% 0.00% -1,078.95% 45.45% 93.18% 86.79% 96.88% -516.67% 41.67% 85.71%
Operating Cash Flow Growth		 -106.62% -60.02% 111.85% 267.30% -1,086.16% 97.83% -341.16% 40.45% 224.06% 86.25%
Free Cash Flow Firm Growth		 -71.20% 111.09% 122.23% 137.65% 131.93% 147.52% -53.43% -97.07% -73.25% -55.26%
Invested Capital Growth		 143.06% -9.38% -23.23% -24.70% -22.32% -21.83% -8.79% -4.51% -7.28% -14.46%
Revenue Q/Q Growth		 -8.32% -2.20% -5.38% 15.13% -11.87% 12.11% -4.41% 16.81% -8.10% 10.56%
EBITDA Q/Q Growth		 -1,438.07% 92.85% -812.53% 128.16% -24.41% -8.96% 18.90% -196.41% 203.27% 27.45%
EBIT Q/Q Growth		 -3,145.25% 80.27% -261.14% 106.89% -69.15% -2.60% 180.90% -660.92% 115.92% 96.36%
NOPAT Q/Q Growth		 -3,734.31% 87.67% -488.72% 107.33% -64.18% -51.82% 357.25% -651.30% 113.87% -483.94%
Net Income Q/Q Growth		 -1,718.04% 69.20% -288.76% 97.29% -85.82% 12.91% 21.87% -436.81% 83.12% 94.13%
EPS Q/Q Growth		 -1,500.00% 69.89% -322.64% 97.32% -100.00% 41.67% 0.00% -428.57% 81.08% 85.71%
Operating Cash Flow Q/Q Growth		 -123.85% 848.07% -52.52% 333.53% -177.03% 224.76% -157.89% 352.49% -31.96% 87.30%
Free Cash Flow Firm Q/Q Growth		 -2.49% 112.23% 96.16% 53.07% -13.09% -5.15% -63.09% -90.39% 694.80% 58.63%
Invested Capital Q/Q Growth		 -2.39% -2.57% -13.64% -8.32% 0.70% -1.96% 0.77% -4.01% -2.22% -9.56%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 65.70% 58.96% 62.09% 65.02% 65.28% 63.73% 68.27% 68.54% 67.32% 66.82%
EBITDA Margin		 -88.11% -6.44% -62.15% 15.20% 13.04% 10.59% 13.17% -10.87% 12.22% 14.08%
Operating Margin		 -98.58% -12.43% -77.32% 4.92% 2.00% 0.86% 4.11% -19.42% 2.93% 5.20%
EBIT Margin		 -98.67% -19.91% -75.99% 4.55% 1.59% 1.38% 4.07% -19.53% 3.38% 6.01%
Profit (Net Income) Margin		 -113.24% -35.66% -146.52% -3.45% -7.28% -5.65% -4.62% -21.24% -3.90% -0.21%
Tax Burden Percent		 111.60% 138.33% 174.16% 108.76% 107.33% 91.08% 117.87% 81.40% 112.19% -137.07%
Interest Burden Percent		 102.84% 129.50% 110.72% -69.75% -425.73% -448.56% -96.41% 133.61% -102.81% 2.51%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 237.07%
Return on Invested Capital (ROIC)		 -66.82% -5.75% -37.97% 2.59% 1.05% 0.47% 2.48% -12.80% 2.01% -7.65%
ROIC Less NNEP Spread (ROIC-NNEP)		 -91.70% -16.99% -69.28% -0.54% -1.79% -2.02% -0.08% -16.02% -0.29% -4.43%
Return on Net Nonoperating Assets (RNNOA)		 -68.82% -10.84% -63.87% -0.43% -2.18% -2.17% -0.14% -27.23% -0.50% -7.21%
Return on Equity (ROE)		 -135.64% -16.59% -101.84% 2.16% -1.14% -1.70% 2.34% -40.03% 1.51% -14.86%
Cash Return on Invested Capital (CROIC)		 -103.70% -5.27% 3.56% 4.70% 14.85% 15.79% 11.00% 2.10% 5.23% 14.02%
Operating Return on Assets (OROA)		 -49.67% -7.85% -37.47% 2.27% 0.73% 0.65% 2.53% -12.87% 2.38% 4.48%
Return on Assets (ROA)		 -57.01% -14.06% -72.24% -1.72% -3.31% -2.65% -2.87% -14.00% -2.74% -0.15%
Return on Common Equity (ROCE)		 -110.34% -13.75% -85.27% 1.81% -0.98% -1.34% 1.84% -31.66% 1.19% -11.75%
Return on Equity Simple (ROE_SIMPLE)		 -49.63% 0.00% -197.88% -201.83% -131.16% 0.00% -15.86% -36.14% -34.40% 0.00%
Net Operating Profit after Tax (NOPAT)		 -89 -11 -64 4.73 1.69 0.82 3.73 -21 2.85 -11
NOPAT Margin		 -69.01% -8.70% -54.12% 3.45% 1.40% 0.60% 2.88% -13.59% 2.05% -7.13%
Net Nonoperating Expense Percent (NNEP)		 24.87% 11.24% 31.31% 3.13% 2.84% 2.49% 2.56% 3.22% 2.30% -3.21%
Return On Investment Capital (ROIC_SIMPLE)		 - -1.32% - - - 0.13% - - - -2.02%
Cost of Revenue to Revenue		 34.30% 41.04% 37.91% 34.98% 34.72% 36.27% 31.73% 31.46% 32.68% 33.18%
SG&A Expenses to Revenue		 61.37% 61.54% 67.91% 54.60% 57.80% 57.86% 60.57% 62.68% 58.35% 56.37%
R&D to Revenue		 3.59% 4.73% 3.17% 2.48% 2.50% 2.41% 2.01% 2.64% 2.74% 2.11%
Operating Expenses to Revenue		 164.29% 71.38% 139.41% 60.10% 63.27% 62.87% 64.15% 87.96% 64.39% 61.62%
Earnings before Interest and Taxes (EBIT)		 -127 -25 -90 6.24 1.92 1.87 5.26 -30 4.70 9.23
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -113 -8.11 -74 21 16 14 17 -16 17 22
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 1.58 0.62 0.44 1.23 1.46 2.39 2.40 3.03 6.34 5.76
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 1.05 0.40 0.16 0.44 0.52 0.81 0.79 0.85 1.70 1.49
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 1.26 0.92 0.84 1.07 1.14 1.42 1.41 1.55 2.46 2.44
Enterprise Value to Revenue (EV/Rev)		 1.85 1.32 1.03 1.23 1.33 1.60 1.57 1.61 2.41 2.10
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 12.07 28.14 41.92 30.63
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 53.64 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 74.87 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 53.27 35.13 65.51 53.26 119.82 77.02 44.84 30.97
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 20.38 19.61 6.71 7.89 12.27 72.15 45.25 16.04
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 1.12 1.01 1.85 1.65 1.74 1.79 1.80 2.13 2.16 1.91
Long-Term Debt to Equity		 1.04 0.93 1.68 1.61 1.66 1.66 1.63 1.82 1.85 1.66
Financial Leverage		 0.75 0.64 0.92 0.80 1.22 1.07 1.66 1.70 1.74 1.63
Leverage Ratio		 3.37 2.75 2.73 2.71 3.65 3.45 3.67 3.86 3.82 3.78
Compound Leverage Factor		 3.46 3.56 3.03 -1.89 -15.53 -15.46 -3.54 5.15 -3.93 0.10
Debt to Total Capital		 52.82% 50.35% 64.96% 62.32% 63.54% 64.10% 64.28% 68.01% 68.31% 65.68%
Short-Term Debt to Total Capital		 3.90% 3.98% 6.02% 1.83% 3.15% 4.52% 5.88% 9.70% 9.80% 8.67%
Long-Term Debt to Total Capital		 48.92% 46.37% 58.94% 60.49% 60.38% 59.58% 58.39% 58.32% 58.51% 57.01%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 4.45% 10.48% 7.56% 8.10% 7.88% 7.72% 7.58% 6.45% 6.46% 6.96%
Common Equity to Total Capital		 42.74% 39.17% 27.48% 29.58% 28.58% 28.18% 28.14% 25.54% 25.22% 27.36%
Debt to EBITDA		 -4.10 -3.44 -2.38 -2.21 -8.67 -17.12 5.76 13.09 12.62 9.06
Net Debt to EBITDA		 -3.64 -3.17 -2.12 -2.00 -7.93 -15.38 5.34 11.98 11.21 7.95
Long-Term Debt to EBITDA		 -3.79 -3.17 -2.16 -2.14 -8.24 -15.91 5.23 11.23 10.81 7.86
Debt to NOPAT		 -3.92 -3.57 -2.68 -2.42 -5.72 -6.90 35.69 -28.07 -30.61 -42.36
Net Debt to NOPAT		 -3.48 -3.29 -2.38 -2.19 -5.23 -6.20 33.10 -25.69 -27.19 -37.18
Long-Term Debt to NOPAT		 -3.63 -3.29 -2.43 -2.35 -5.44 -6.42 32.42 -24.07 -26.21 -36.77
Altman Z-Score		 0.24 0.24 -0.01 0.46 0.48 0.64 0.67 0.51 1.20 1.20
Noncontrolling Interest Sharing Ratio		 18.66% 17.11% 16.27% 16.24% 13.98% 21.24% 21.41% 20.90% 21.06% 20.95%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.94 0.90 1.57 1.46 1.55 1.53 1.53 1.33 1.41 1.31
Quick Ratio		 0.58 0.55 0.84 0.83 0.87 0.91 0.87 0.73 0.78 0.80
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -534 65 128 196 170 162 60 5.74 46 72
Operating Cash Flow to CapEx		 -42.51% 0.00% 69.94% 772.73% -408.40% 2,811.38% -2,063.57% 19,690.91% 16,118.75% 3,366.20%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.50 0.39 0.49 0.50 0.46 0.47 0.62 0.66 0.70 0.75
Accounts Receivable Turnover		 4.35 3.92 4.32 3.89 4.10 3.96 4.28 4.18 4.73 4.58
Inventory Turnover		 3.03 2.47 2.42 2.28 2.14 2.09 1.95 1.95 1.95 2.01
Fixed Asset Turnover		 0.00 20.31 16.74 15.25 0.00 16.00 14.71 14.55 16.06 18.02
Accounts Payable Turnover		 11.48 6.75 6.67 5.63 10.17 6.17 6.94 5.46 10.62 7.92
Days Sales Outstanding (DSO)		 83.93 93.10 84.46 93.87 88.97 92.29 85.21 87.34 77.21 79.64
Days Inventory Outstanding (DIO)		 120.42 147.64 150.92 159.79 170.61 174.52 187.43 186.73 186.89 181.27
Days Payable Outstanding (DPO)		 31.79 54.05 54.70 64.84 35.89 59.20 52.62 66.82 34.36 46.08
Cash Conversion Cycle (CCC)		 172.56 186.70 180.68 188.82 223.69 207.61 220.03 207.25 229.74 214.83
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 756 737 636 583 587 576 580 557 545 493
Invested Capital Turnover		 0.97 0.66 0.70 0.75 0.75 0.78 0.86 0.94 0.98 1.07
Increase / (Decrease) in Invested Capital		 445 -76 -193 -191 -169 -161 -56 -26 -43 -83
Enterprise Value (EV)		 955 675 531 626 669 817 821 864 1,338 1,202
Market Capitalization		 542 203 84 226 259 415 412 458 943 852
Book Value per Share		 $4.43 $4.18 $2.42 $2.34 $2.26 $2.20 $2.16 $1.90 $1.84 $1.82
Tangible Book Value per Share		 ($9.39) ($4.14) ($4.29) ($4.21) ($4.11) ($4.02) ($3.88) ($3.53) ($3.38) ($3.26)
Total Capital		 804 830 686 619 621 616 609 591 590 541
Total Debt		 424 418 446 386 395 395 391 402 403 355
Total Long-Term Debt		 393 385 404 375 375 367 355 345 345 308
Net Debt		 377 385 396 350 361 355 363 368 358 312
Capital Expenditures (CapEx)		 1.65 -5.16 3.56 1.40 2.04 0.37 0.29 0.08 0.06 0.57
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -20 -29 107 63 81 83 103 103 102 71
Debt-free Net Working Capital (DFNWC)		 14 1.61 154 93 108 120 128 135 145 112
Net Working Capital (NWC)		 -17 -31 113 82 89 93 93 77 87 65
Net Nonoperating Expense (NNE)		 57 34 110 9.46 10 8.47 9.71 12 8.27 -11
Net Nonoperating Obligations (NNO)		 377 324 396 350 361 355 363 368 358 307
Total Depreciation and Amortization (D&A)		 14 17 16 15 14 12 12 13 12 12
Debt-free, Cash-free Net Working Capital to Revenue		 -3.94% -5.58% 20.79% 12.43% 16.18% 16.28% 19.75% 19.14% 18.36% 12.31%
Debt-free Net Working Capital to Revenue		 2.71% 0.32% 29.95% 18.18% 21.52% 23.49% 24.56% 25.09% 26.12% 19.56%
Net Working Capital to Revenue		 -3.35% -6.14% 21.91% 15.97% 17.62% 18.05% 17.71% 14.42% 15.71% 11.38%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.76) ($0.53) ($2.24) ($0.06) ($0.12) ($0.07) ($0.07) ($0.37) ($0.07) ($0.01)
Adjusted Weighted Average Basic Shares Outstanding		 61.67M 61.39M 62.12M 62.55M 62.82M 62.65M 63.38M 64.06M 65.26M 64.55M
Adjusted Diluted Earnings per Share		 ($1.76) ($0.53) ($2.24) ($0.06) ($0.12) ($0.07) ($0.07) ($0.37) ($0.07) ($0.01)
Adjusted Weighted Average Diluted Shares Outstanding		 61.67M 61.39M 62.12M 62.55M 62.82M 62.65M 63.38M 64.06M 65.26M 64.55M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 77.74M 78.05M 78.27M 78.58M 78.75M 79.17M 79.61M 80.97M 81.15M 81.94M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.90 -7.51 -8.99 5.33 1.61 0.97 3.94 1.96 4.61 7.52
Normalized NOPAT Margin		 -0.70% -5.97% -7.55% 3.89% 1.33% 0.72% 3.04% 1.30% 3.32% 4.89%
Pre Tax Income Margin		 -101.47% -25.78% -84.13% -3.17% -6.78% -6.21% -3.92% -26.09% -3.48% 0.15%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Bioventus Inc. (NYSE: BVS) has shown a fluctuating financial performance over the past four years, with trends in revenue, profitability, cash flow, and balance sheet strength demonstrating both challenges and areas of improvement.

Positive highlights:

  • Operating revenue increased steadily from approximately $119 million in Q1 2023 to $153.6 million in Q4 2024, indicating top-line growth over the last eight quarters.
  • Gross profit grew from about $73.9 million in Q1 2023 to $102.7 million in Q4 2024, reflecting effective cost management relative to revenue growth.
  • Net cash from continuing operating activities improved significantly, reaching $19.3 million in Q4 2024 from a negative $6.0 million in Q1 2024, showing stronger cash generation.
  • The company reduced overall debt through substantial repayments, with Q4 2024 financing activities showing $49.6 million in debt repayments, consistent with deleveraging efforts.
  • Cash and equivalents rose from about $25.2 million in Q1 2024 to $43.1 million in Q3 2024 before stabilizing, providing liquidity support.
  • Total equity improved from $148.7 million in Q3 2024 up to about $217.4 million in Q1 2023, helped by reduced losses and operational improvements.

Neutral observations:

  • Selling, General & Administrative expenses remained high, around $78 million to $94 million quarterly, indicating ongoing investment but also pressure on margins.
  • Research & Development expenses fluctuated moderately between $2.6 million and $4.0 million quarterly, consistent with ongoing innovation efforts.
  • Depreciation expenses averaged around $1.5 million to $2.3 million quarterly, reflecting stable asset base amortizations.
  • The company showed some positive net cash from investing activities in Q3 and Q4 2024 primarily from divestitures, which supported cash flow but may indicate asset sales.

Negative aspects and challenges:

  • Bioventus has consistently reported net losses continuing operations over this period, though the losses have narrowed from over -$100 million in early 2023 to about -$318,000 in Q4 2024.
  • Total operating expenses remain elevated and volatile, driven by impairment charges which peaked at over $78 million in Q1 2023 and continued at multi-million dollar levels late in 2024.
  • The company’s balance sheet shows high levels of long-term debt, around $345 million to $404 million in recent quarters, which poses leverage risks despite recent debt repayments.
  • Negative earnings per share dominated the period, although improving from -$2.24 in Q1 2023 to -$0.01 in Q4 2024, indicating ongoing challenges to profitability on a per-share basis.
  • The interest and investment income line consistently reflects a significant expense rather than income, negatively impacting pre-tax income each quarter.
  • The company’s retained earnings remain deeply negative, worsening from around -$304 million in early 2023 to more than -$350 million in late 2024, reflecting accumulated losses over time.

In summary, Bioventus has made solid progress growing revenue and improving cash flow generation while managing some large impairment charges. The company is working to reduce losses and deleverage its balance sheet but continues to face profitability and leverage headwinds that retail investors should monitor closely.

10/25/25 01:16 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Bioventus' Financials

When does Bioventus' fiscal year end?

According to the most recent income statement we have on file, Bioventus' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Bioventus' net income changed over the last 2 years?

Bioventus' net income appears to be on a downward trend, with a most recent value of -$43.83 million in 2024, falling from -$213.39 million in 2022. The previous period was -$195.63 million in 2023. Find out what analysts predict for Bioventus in the coming months.

What is Bioventus' operating income?
Bioventus' total operating income in 2024 was -$11.98 million, based on the following breakdown:
  • Total Gross Profit: $388.23 million
  • Total Operating Expenses: $400.21 million
How has Bioventus' revenue changed over the last 2 years?

Over the last 2 years, Bioventus' total revenue changed from $512.12 million in 2022 to $573.28 million in 2024, a change of 11.9%.

How much debt does Bioventus have?

Bioventus' total liabilities were at $542.35 million at the end of 2024, a 8.0% decrease from 2023, and a 43.5% decrease since 2022.

How much cash does Bioventus have?

In the past 2 years, Bioventus' cash and equivalents has ranged from $30.19 million in 2022 to $41.58 million in 2024, and is currently $41.58 million as of their latest financial filing in 2024.

How has Bioventus' book value per share changed over the last 2 years?

Over the last 2 years, Bioventus' book value per share changed from 4.18 in 2022 to 1.82 in 2024, a change of -56.4%.


Related Companies

This page (NYSE:BVS) was last updated on 10/25/2025 by MarketBeat.com Staff
From Our Partners
NEW LAW: Congress Approves Setup For Digital Dollar?
Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...
Goldco Precious Metals | Sponsoredtc pixel
If You Keep Cash In A U.S. Bank Account… Read This NOW
The Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...
Banyan Hill Publishing | Sponsoredtc pixel
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsoredtc pixel
$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...
Brownstone Research | Sponsoredtc pixel
Claim Your Share of $5.39 BILLION in AI Equity Checks
The U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...
Angel Publishing | Sponsoredtc pixel
Move $1,000 into this stock before Nov 6
The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...
Altimetry | Sponsoredtc pixel
$4,200 gold is nice ... but here’s what most gold bugs are missing
Gold just surged past $4,200, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...
Weiss Ratings | Sponsoredtc pixel
Buy UBER immediately
BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...
Chaikin Analytics | Sponsoredtc pixel